RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Ryvu Therapeutics Stock

Ryvu Therapeutics Dividend 2024

Ryvu Therapeutics Dividend

0 PLN

Ryvu Therapeutics Dividend yield

Ticker

RVU.WA

ISIN

PLSELVT00013

WKN

A1JUH2

How much dividend does Ryvu Therapeutics 2024 pay?

According to the latest status from October 2024, Ryvu Therapeutics paid a total of 0 PLN per share in dividends within the last 12 months. With the current Ryvu Therapeutics price of 49.05 PLN, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

=

Historical Ryvu Therapeutics Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend

Is the Ryvu Therapeutics Dividend Safe?

Ryvu Therapeutics has been increasing the dividend for 0 years.

Over the past 10 years, Ryvu Therapeutics has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Dividend Details

Understanding Ryvu Therapeutics's Dividend Distributions

Ryvu Therapeutics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Ryvu Therapeutics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Ryvu Therapeutics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Ryvu Therapeutics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Ryvu Therapeutics Aktienanalyse

What does Ryvu Therapeutics do?

Ryvu Therapeutics SA is a Polish biotechnology company specializing in the research and development of innovative therapies for various types of cancers. The company was founded in 2015 and is headquartered in Krakow. Ryvu Therapeutics SA has gained a good reputation since its establishment and has attracted numerous renowned investors and partners. The company's business model focuses on the research and development of drugs based on new molecular therapies that can inhibit the activity of specific proteins in cancer patients. The company's strategy is to develop a wide range of innovative therapies with different mechanisms of action to maximize the potential of helping cancer patients. Ryvu Therapeutics SA operates in three main areas: research and development, preclinical development, and clinical development. The company has a highly experienced team of scientists and researchers dedicated to developing new anti-cancer drugs. The research focus is on identifying new therapeutic targets and molecules or compounds that can inhibit the activity of these targets. After identifying promising molecules in the research phase, the company conducts extensive preclinical studies to assess the safety and efficacy of the drug candidates. Different models are used to test the effects of the new therapies in vitro and in vivo. Upon successful completion of the preclinical phase, the company moves on to clinical development, where the effectiveness and safety of the drugs are evaluated in clinical trials in humans. Phase I clinical trials are conducted to determine the tolerability and dosage of the drug candidates. Phase II and III trials investigate the efficacy and safety of the drug in a larger number of patients. Ryvu Therapeutics SA has several molecules and compounds in its portfolio that are currently in different stages of development. Some examples include SEL120, a potential new drug that inhibits the activity of the CDK8 protein, which plays a crucial role in the development of cancer. SEL120 is currently in Phase I clinical trials. SEL201 is another drug candidate that targets CDK8 and is still in the preclinical research phase. SEL110 is a small molecule that targets the BCL-XL protein and has the potential to be effective against multiple types of cancer. It is currently in the early phase of clinical development. In conclusion, Ryvu Therapeutics SA is an innovative biotech company specializing in the development of new cancer therapies. The company already has several promising drug candidates in its portfolio, targeting different therapeutic targets and currently in various stages of development. Ryvu Therapeutics SA shows great potential to play a significant role in the treatment of cancer. Ryvu Therapeutics is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Ryvu Therapeutics stock

How much dividend does Ryvu Therapeutics pay?

Over the past 12 months, Ryvu Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Ryvu Therapeutics is expected to pay a dividend of 0 PLN.

What is the dividend yield of Ryvu Therapeutics?

The current dividend yield of Ryvu Therapeutics is .

When does Ryvu Therapeutics pay dividends?

Ryvu Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Ryvu Therapeutics?

Ryvu Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Ryvu Therapeutics?

For the upcoming 12 months, dividends amounting to 0 PLN are expected. This corresponds to a dividend yield of 0 %.

In which sector is Ryvu Therapeutics located?

Ryvu Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Ryvu Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Ryvu Therapeutics from 10/28/2024 amounting to 0 PLN, you needed to have the stock in your portfolio before the ex-date on 10/28/2024.

When did Ryvu Therapeutics pay the last dividend?

The last dividend was paid out on 10/28/2024.

What was the dividend of Ryvu Therapeutics in the year 2023?

In the year 2023, Ryvu Therapeutics distributed 0 PLN as dividends.

In which currency does Ryvu Therapeutics pay out the dividend?

The dividends of Ryvu Therapeutics are distributed in PLN.

Andere Kennzahlen von Ryvu Therapeutics

Our stock analysis for Ryvu Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Ryvu Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.